Special Issue "Cyclic AMP/PKA/Epac Signaling in Health and Disease"
Deadline for manuscript submissions: closed (15 June 2022) | Viewed by 20932
Interests: cardioprotection; cardioplegia; cardiac remodeling post-acute infarction; molecular changes in diseased heart; ischemia; mitochondria; calcium
Special Issues, Collections and Topics in MDPI journals
2. Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
Interests: cardiac physiology; neurophysiology; cyclic AMP/PKA/Epac signaling
Cellular signaling associated with cAMP (cyclic AMP) and its target proteins PKA (protein kinase A) and Epac (guanine nucleotide exchange protein directly activated by cAMP) is important in regulating the function of various cell types including those in the cardiovascular, respiratory, excretory, brain, and other systems. The key issues related to cAMP signaling particularly in disease and prevention, remain unanswered or not fully understood. For example, the interaction between PKA and Epac pathways and their interplay with calcium regulation, oxidative stress, and the mitochondria. A major advance in this area has been the availability of cell-permeable cAMP analogues, which have been used to elucidate relevant cellular activities and to demonstrate protection against pathologies. Nonetheless, more work is needed to understand the exact role PKA and different Epac isoforms as well as their expression/cellular distribution in different cell types.
This Special Issue aims to update the current knowledge on the role of cAMP/PKA/Epac signaling in different cell types and to integrate this information to better understand its role in health and disease. This could be related to virtually any pathological condition in different cells, organs, and systems. It is anticipated that such knowledge will help in formulating novel therapeutic interventions that target this signaling pathway.
We look forward to your contributions.
Prof. Dr. M.-Saadeh Suleiman
Dr. Igor Khaliulin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cardiovascular diseases
- renal vascular diseases
- cerebrovascular diseases
- oxidative stress
- cAMP analougues